Hyloris Pharmaceuticals Valuation

Is 0AB6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0AB6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0AB6's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0AB6's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0AB6?

Key metric: As 0AB6 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0AB6. This is calculated by dividing 0AB6's market cap by their current revenue.
What is 0AB6's PS Ratio?
PS Ratio	23.2x
Sales	€6.94m
Market Cap	€160.72m

0AB6 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	19.4x
Enterprise Value/EBITDA	-10x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0AB6's PS Ratio compare to its peers?

The above table shows the PS ratio for 0AB6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.4x
ANCR Animalcare Group	2x	3.8%	UK£148.5m
APH Alliance Pharma	1.3x	5.2%	UK£246.0m
REDX Redx Pharma	13.9x	-37.6%	UK£58.3m
AGY Allergy Therapeutics	4.4x	19.2%	UK£243.6m
0AB6 Hyloris Pharmaceuticals	23.2x	70.3%	€160.7m

Price-To-Sales vs Peers: 0AB6 is expensive based on its Price-To-Sales Ratio (23.2x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does 0AB6's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
EAH ECO Animal Health Group	0.5x	5.9%	US$56.04m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0AB6 is expensive based on its Price-To-Sales Ratio (23.2x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 0AB6's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0AB6 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0AB6's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0AB6 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€5.70	€11.10 +94.7%	55.0%	€17.20	€5.00	n/a	2
Nov ’25	n/a	€11.10 0%	55.0%	€17.20	€5.00	n/a	2
Oct ’25	€5.74	€11.10 +93.4%	55.0%	€17.20	€5.00	n/a	2
Sep ’25	€5.70	€11.10 +94.7%	55.0%	€17.20	€5.00	n/a	2
Aug ’25	n/a	€19.10 0%	9.9%	€21.00	€17.20	n/a	2
Jul ’25	n/a	€21.55 0%	2.6%	€22.10	€21.00	n/a	2
Jun ’25	n/a	€21.55 0%	2.6%	€22.10	€21.00	n/a	2
May ’25	€11.70	€21.55 +84.2%	2.6%	€22.10	€21.00	n/a	2
Apr ’25	€11.35	€20.65 +81.9%	1.7%	€21.00	€20.30	n/a	2
Mar ’25	€12.25	€19.90 +62.4%	2.0%	€20.30	€19.50	n/a	2
Feb ’25	€13.25	€19.90 +50.2%	2.0%	€20.30	€19.50	n/a	2
Jan ’25	€12.75	€19.90 +56.1%	2.0%	€20.30	€19.50	n/a	2
Dec ’24	€12.50	€19.90 +59.2%	2.0%	€20.30	€19.50	n/a	2
Nov ’24	€12.45	€19.90 +59.9%	2.0%	€20.30	€19.50	n/a	2
Oct ’24	n/a	€19.25 0%	1.3%	€19.50	€19.00	€5.74	2
Jul ’24	n/a	€19.75 0%	1.3%	€20.00	€19.50	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

4.0%

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.7%

-6.3%